Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients.

Literature DB >> 15329045

Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients.

Abstract

Nicorandil (Adancor, Angicor, Dancor, Nikoril [Europe], Ikorel [Europe and Oceania], Sigmart [Japan, Korea and Taiwan]) is an adenosine triphosphate (ATP)-sensitive potassium (KATP) channel agonist with nitrate-like properties used in the management of stable angina pectoris. With well established monotherapeutic antianginal activity and a beneficial effect (when added to optimal antianginal therapy) on clinical outcomes in high-risk patients with stable angina, twice-daily oral nicorandil is a useful alternative or addition to other antianginal therapy.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2004 PMID： 15329045 DOI： 10.2165/00003495-200464170-00012

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

83 in total

1. Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris.

Authors: R Rajaratnam; D B Brieger; R Hawkins; S B Freedman
Journal: Am J Cardiol Date: 1999-04-01 Impact factor: 2.778

2. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty.

Authors: Tsung-Ming Lee; Sheng-Fang Su; Tsai-Fwu Chou; Yuan-Teh Lee; Chang-Her Tsai
Journal: Circulation Date: 2002-01-22 Impact factor: 29.690

3. Cardioprotective effect of intravenous nicorandil in patients with successful reperfusion for acute myocardial infarction.

Authors: Y Kobayashi; Y Goto; S Daikoku; A Itoh; S Miyazaki; S Ohshima; H Nonogi; K Haze
Journal: Jpn Circ J Date: 1998-03

4. Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty.

Authors: T Kato; T Kamiyama; Y Maruyama; S Tanaka; N Yoshimoto
Journal: Am Heart J Date: 2001-06 Impact factor: 4.749

5. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.

Authors:
Journal: Lancet Date: 2002-04-13 Impact factor: 79.321

6. Comparison of nicorandil and atenolol in stable angina pectoris.

Authors: L O Hughes; E L Rose; A Lahiri; E B Raftery
Journal: Am J Cardiol Date: 1990-09-15 Impact factor: 2.778

7. Antiischemic effects of nicorandil during coronary angioplasty in humans.

Authors: S Saito; T Mizumura; T Takayama; J Honye; T Fukui; T Kamata; M Moriuchi; K Hibiya; Y Tamura; Y Ozawa
Journal: Cardiovasc Drugs Ther Date: 1995-03 Impact factor: 3.727

8. Nicorandil preserves mitochondrial function during ischemia in perfused rat heart.

Authors: Takeshi Iwai; Kouichi Tanonaka; Kanataka Motegi; Rie Inoue; Sayaka Kasahara; Satoshi Takeo
Journal: Eur J Pharmacol Date: 2002-06-20 Impact factor: 4.432

9. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients.

Authors: G Döring
Journal: J Cardiovasc Pharmacol Date: 1992 Impact factor: 3.105

10. Rationale and design of a large-scale trial using nicorandil as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by a K-ATP channel opener (J-WIND-KATP).

Authors: Tetsuo Minamino; Kim Jiyoong; Masanori Asakura; Yasunori Shintani; Hiroshi Asanuma; Masafumi Kitakaze
Journal: Circ J Date: 2004-02 Impact factor: 2.993

11 in total

Review 1. K(ATP) channel therapeutics at the bedside.

Authors: A Jahangir; Andre Terzic
Journal: J Mol Cell Cardiol Date: 2005-07 Impact factor: 5.000

Review 2. Recent developments in nitric oxide donor drugs.

Authors: M R Miller; I L Megson
Journal: Br J Pharmacol Date: 2007-04-02 Impact factor: 8.739

3. Recurrence of Takotsubo cardiomyopathy with coronary slow flow phenomenon.

Authors: Tomotake Tokunou; Kenji Sadamatsu
Journal: J Cardiol Cases Date: 2012-03-16

Review 4. Potassium channels: a review of broadening therapeutic possibilities for neurological diseases.

Authors: Snezana Maljevic; Holger Lerche
Journal: J Neurol Date: 2012-11-11 Impact factor: 4.849

Review 5. Use of nicorandil in cardiovascular disease and its optimization.

Authors: Shigeo Horinaka
Journal: Drugs Date: 2011-06-18 Impact factor: 9.546

Review 6. [New agents for the therapy of angina pectoris].

Authors: T Meinertz; R Köster
Journal: Internist (Berl) Date: 2011-07 Impact factor: 0.743

Review 7. Stable angina pectoris: antianginal therapies and future directions.

Authors: Bernard R Chaitman; Abhay A Laddu
Journal: Nat Rev Cardiol Date: 2011-08-30 Impact factor: 32.419

8. Evaluation of the effects of nicorandil and its molecular precursor (without radical NO) on proliferation and apoptosis of 786-cell.

Authors: Natália Aparecida de Paula; Andressa Megumi Niwa; Diogo Campos Vesenick; Carolina Panis; Rubens Cecchini; Angelo de Fátima; Lúcia Regina Ribeiro; Mário Sérgio Mantovani
Journal: Cytotechnology Date: 2013-01-17 Impact factor: 2.058

Review 9. Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.

Authors: Richard Kones
Journal: Vasc Health Risk Manag Date: 2010-09-07

Review 10. Medical therapy versus percutaneous coronary interventions for patients with stable and unstable coronary artery disease.

Authors: Bertram Pitt
Journal: Curr Atheroscler Rep Date: 2008-08 Impact factor: 5.113